Drug intelligence / Profile preview

Menomedin

Development stage
Unknown
Lead developer
NutriMed
Modality
Small Molecules
Administration
Oral
01

Overview

Menomedin is a multi-component nutraceutical developed by NutriMed Group, specifically formulated to alleviate symptoms associated with menopause and perimenopause. It contains a combination of standardized herbal extracts, including red clover (Trifolium pratense), black cohosh (Cimicifuga racemosa), and sage (Salvia officinalis). These components work synergistically to provide phytoestrogenic activity and modulate neuroendocrine functions, helping to reduce the frequency and intensity of hot flashes, night sweats, and emotional instability. Red clover is rich in isoflavones that mimic estrogen, while black cohosh is traditionally used for its effects on the hypothalamic-pituitary system and neurotransmitter modulation, and sage helps manage excessive sweating. It is marketed as a non-hormonal alternative for managing climacteric syndrome.

Brand names
Menomedin
Other names
Меномедин
02

Targets

MOR (Mu opioid receptor)ER (Estrogen receptor)5-HT (Serotonin receptors)

Beyond the preview

Go deeper on Menomedin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Menomedin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call